Search

Search Results

1. Preclinical comparison of [¹⁷⁷Lu]Lu-rhPSMA-10.1 and [¹⁷⁷Lu]Lu-rhPSMA-10.2 for endoradiotherapy of prostate cancer: biodistribution and dosimetry studies

   Background

   Radiohybrid PSMA-targeted ligands (rhPSMA) have been introduced as a novel platform for theranostic applications. Among a variety of...

   Alexander Wurzer, Francesco De Rose, ... Calogero D’Alessandria in EJNMMI Radiopharmacy and Chemistry

   Article Open access 26 February 2024
   

2. Intricacies in the Preparation of Patient Doses of [¹⁷⁷Lu]Lu-Rituximab and [¹⁷⁷Lu]Lu-Trastuzumab Using Low Specific Activity [¹⁷⁷Lu]LuCl₃: Methodological Aspects

   The development of humanized monoclonal antibodies (MAbs) with Lutetium-177 ([ ¹⁷⁷ Lu]Lu ³⁺ ) has brought a paradigm shift in the arena of targeted...

   Avik Chakraborty, Arpit Mitra, ... Sharmila Banerjee in Molecular Imaging and Biology

   Article 06 September 2023
   

3. Comparison of novel PSMA-targeting [¹⁷⁷Lu]Lu-P17-087 with its albumin binding derivative [¹⁷⁷Lu]Lu-P17-088 in metastatic castration-resistant prostate cancer patients: a first-in-human study

   Purpose

   Prostate-specific membrane antigen (PSMA) is a promising target for diagnosis and radioligand therapy (RLT) of prostate cancer. Two novel...

   Linlin Li, Jiarou Wang, ... Zhaohui Zhu in European Journal of Nuclear Medicine and Molecular Imaging

   Article 25 April 2024
   

4. Prediction of [¹⁷⁷Lu]Lu-DOTA-TATE therapy response using the absorbed dose estimated from [¹⁷⁷Lu]Lu-DOTA-TATE SPECT/CT in patients with metastatic neuroendocrine tumour

   Background

   Peptide receptor radionuclide therapy (PRRT) with [ ¹⁷⁷ Lu]Lu-DOTA-TATE has shown efficacy in patients with metastatic neuroendocrine...

   Se** Ha, Yong-il Kim, ... **-Sook Ryu in EJNMMI Physics

   Article Open access 05 February 2024
   

5. [¹⁷⁷Lu]Lu-PSMA-617 theranostic probe for hepatocellular carcinoma imaging and therapy

   Purpose

   This study aimed to explore the feasibility of using [ ¹⁷⁷ Lu]Lu-prostate-specific membrane antigen (PSMA)-617 and [ ¹⁷⁷ Lu]Lu-Evans blue...

   Qiaomiao Lu, Yu Long, ... **aoli Lan in European Journal of Nuclear Medicine and Molecular Imaging

   Article 06 March 2023
   

6. p53 stabilisation potentiates [¹⁷⁷Lu]Lu-DOTATATE treatment in neuroblastoma xenografts

   Purpose

   Molecular radiotherapy is a treatment modality that is highly suitable for targeting micrometastases and [ ¹⁷⁷ Lu]Lu-DOTATATE is currently...

   Hanna Berglund, Sara Lundsten Salomonsson, ... Marika Nestor in European Journal of Nuclear Medicine and Molecular Imaging

   Article Open access 12 October 2023
   

7. Preparation of Patient Doses of [¹⁷⁷Lu]Lu-DOTATATE and [¹⁷⁷Lu]Lu-PSMA-617 with Carrier Added (CA) and No Carrier Added (NCA) ¹⁷⁷Lu

   Purpose

   [ ¹⁷⁷ Lu]Lu-DOTATATE and [ ¹⁷⁷ Lu]Lu-PSMA-617 used for targeted radionuclide therapy are very often prepared in the hospital radiopharmacy. The...

   Raviteja Nanabala, Maroor Raghavan Ambikalmajan Pillai, Buvaneswari Gopal in Nuclear Medicine and Molecular Imaging

   Article 07 October 2022
   

8. Dosimetry and pharmacokinetics of [¹⁷⁷Lu]Lu-satoreotide tetraxetan in patients with progressive neuroendocrine tumours

   Purpose

   To evaluate the dosimetry and pharmacokinetics of the novel radiolabelled somatostatin receptor antagonist [ ¹⁷⁷ Lu]Lu-satoreotide tetraxetan...

   Seval Beykan Schürrle, Uta Eberlein, ... Michael Lassmann in European Journal of Nuclear Medicine and Molecular Imaging

   Article Open access 26 March 2024
   

9. Urinary excretion kinetics of [¹⁷⁷Lu]Lu-PSMA-617

   Introduction

   For the implementation of suitable radiation safety measures in [ ¹⁷⁷ Lu]Lu-PSMA-617 therapy, additional insight into excretion kinetics...

   Maarten de Bakker, Noa Dominicus, ... Steffie M. B. Peters in European Journal of Nuclear Medicine and Molecular Imaging

   Article Open access 08 July 2023
   

10. Improved quality control of [¹⁷⁷Lu]Lu-PSMA I&T

    Background

    Targeted radionuclide therapy with [ ¹⁷⁷ Lu]Lu-PSMA I&T (zadavotide guraxetan) has proven high efficacy and safety in treating patients with...

    Martin Kraihammer, Piotr Garnuszek, ... Clemens Decristoforo in EJNMMI Radiopharmacy and Chemistry

    Article Open access 27 March 2023
    

11. [¹⁷⁷Lu]Lu-labeled anti-claudin-18.2 antibody demonstrated radioimmunotherapy potential in gastric cancer mouse xenograft models

    Purpose

    Gastric cancer (GC), one of the most prevalent and deadliest tumors worldwide, is often diagnosed at an advanced stage with limited treatment...

    Ziqing Zeng, Liqiang Li, ... Hua Zhu in European Journal of Nuclear Medicine and Molecular Imaging

    Article 08 December 2023
    

12. In vitro characterisation of [¹⁷⁷Lu]Lu-DOTA-C595 as a novel radioimmunotherapy for MUC1-CE positive pancreatic cancer

    Background

    Pancreatic ductal adenocarcinoma (PDAC) continues to be a malignancy with an unmet clinical demand. Development of radioimmunoconjugates...

    Ashleigh Hull, William Hsieh, ... Eva Bezak in EJNMMI Radiopharmacy and Chemistry

    Article Open access 14 August 2023
    

13. Lutetium [¹⁷⁷Lu]-DOTA-TATE in gastroenteropancreatic-neuroendocrine tumours: rationale, design and baseline characteristics of the Italian prospective observational (REAL-LU) study

    Purpose

    Gastroenteropancreatic -neuroendocrine tumours (GEP-NETs) are commonly treated with surgical resection or long-term therapies for tumour...

    Secondo Lastoria, Marcello Rodari, ... Ettore Seregni in European Journal of Nuclear Medicine and Molecular Imaging

    Article Open access 22 May 2024
    

14. [¹⁷⁷Lu]Lu-PSMA-617 as first-line systemic therapy in patients with metastatic castration-resistant prostate cancer: a real-world study

    Purpose

    The use of [ ¹⁷⁷ Lu]Lu-PSMA-617 radioligand therapy has become increasingly recognized as a viable therapeutic approach for patients in the...

    Swayamjeet Satapathy, Madhav Prasad Yadav, ... Chandrasekhar Bal in European Journal of Nuclear Medicine and Molecular Imaging

    Article 12 March 2024
    

15. The Balance Between the Therapeutic Efficacy and Safety of [¹⁷⁷Lu]Lu-NeoB in a Preclinical Prostate Cancer Model

    Purpose

    Radiolabeled NeoB is a promising gastrin-releasing peptide receptor (GRPR)–targeting radiopharmaceutical for theranostics of GRPR-expressing...

    Marjolein Verhoeven, Joost Haeck, ... Simone U. Dalm in Molecular Imaging and Biology

    Article Open access 28 August 2023
    

16. Development of [¹⁷⁷Lu]Lu-LNC1003 for radioligand therapy of prostate cancer with a moderate level of PSMA expression

    Purpose

    Evans blue as an albumin binder has been widely used to improve pharmacokinetics and enhance tumor uptake of radioligands, including...

    Xuejun Wen, Pengfei Xu, ... **aoyuan Chen in European Journal of Nuclear Medicine and Molecular Imaging

    Article 25 April 2023
    

17. Quantification of biochemical PSA dynamics after radioligand therapy with [¹⁷⁷Lu]Lu-PSMA-I&T using a population pharmacokinetic/pharmacodynamic model

    Background

    There is an unmet need for prediction of treatment outcome or patient selection for [ ¹⁷⁷ Lu]Lu-PSMA therapy in patients with metastatic...

    Hinke Siebinga, Berlinda J. de Wit-van der Veen, ... Alwin D. R. Huitema in EJNMMI Physics

    Article Open access 24 April 2024
    

18. Radiation exposure assessment of nuclear medicine staff administering [¹⁷⁷Lu]Lu-DOTA-TATE with active and passive dosimetry

    Background

    The use of lutetium-177 ( ¹⁷⁷ Lu)-based radiopharmaceuticals in peptide receptor nuclear therapy is increasing, but so is the number of...

    Mercedes Riveira-Martin, Lara Struelens, ... Antonio López Medina in EJNMMI Physics

    Article Open access 14 November 2023
    

19. Estimation of relative biological effectiveness of ²²⁵Ac compared to ¹⁷⁷Lu during [²²⁵Ac]Ac-PSMA and [¹⁷⁷Lu]Lu-PSMA radiopharmaceutical therapy using TOPAS/TOPAS-nBio/MEDRAS

    Aim

    Over recent years, [ ²²⁵ Ac]Ac-PSMA and [ ¹⁷⁷ Lu]Lu-PSMA radiopharmaceutical therapy have evolved as a promising treatment option for advanced...

    Mikhail Rumiantcev, Wei Bo Li, ... Astrid Delker in EJNMMI Physics

    Article Open access 11 September 2023
    

20. [¹⁷⁷Lu]Lu-DOTAGA.Glu.(FAPi)₂ Radionuclide Therapy: a New Treatment Option for Patients with Glioblastoma Multiforme

    In this case report, we present the clinical management of a 52-year-old female patient with a recurrent right temporo-parietal glioblastoma...

    Sanjana Ballal, Madhav P. Yadav, ... Chandrasekhar Bal in Nuclear Medicine and Molecular Imaging

    Article 14 July 2023